Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Aetiology
Age of onset
Environment
Epidemiology
Neuromyelitis optica
Risk factors
Sex
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
received:
14
03
2024
accepted:
16
05
2024
revised:
15
05
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
Aquaporin-4 (AQP4) antibody-associated neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated inflammatory disease of the central nervous system. We have undertaken a systematic review and meta-analysis to ascertain the sex ratio and mean age of onset for AQP4 antibody associated NMOSD. We have also explored factors that impact on these demographic data. A systematic search of databases was conducted according to the PRISMA guidelines. Articles reporting sex distribution and age of onset for AQP4 antibody-associated NMSOD were reviewed. An initially inclusive approach involving exploration with regression meta-analysis was followed by an analysis of just AQP4 antibody positive cases. A total of 528 articles were screened to yield 89 articles covering 19,415 individuals from 88 population samples. The female:male sex ratio was significantly influenced by the proportion of AQP4 antibody positive cases in the samples studied (p < 0.001). For AQP4 antibody-positive cases the overall estimate of the sex ratio was 8.89 (95% CI 7.78-10.15). For paediatric populations the estimate was 5.68 (95% CI 4.01-8.03) and for late-onset cases, it was 5.48 (95% CI 4.10-7.33). The mean age of onset was significantly associated with the mean life expectancy of the population sampled (p < 0.001). The mean age of onset for AQP4 antibody-positive cases in long-lived populations was 41.7 years versus 33.3 years in the remainder. The female:male sex ratio and the mean age of onset of AQP4 antibody-associated NMOSD are significantly higher than MS. The sex ratio increases with the proportion of cases that are positive for AQP4 antibodies and the mean age of onset increases with population life expectancy.
Sections du résumé
BACKGROUND
BACKGROUND
Aquaporin-4 (AQP4) antibody-associated neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated inflammatory disease of the central nervous system. We have undertaken a systematic review and meta-analysis to ascertain the sex ratio and mean age of onset for AQP4 antibody associated NMOSD. We have also explored factors that impact on these demographic data.
METHODS
METHODS
A systematic search of databases was conducted according to the PRISMA guidelines. Articles reporting sex distribution and age of onset for AQP4 antibody-associated NMSOD were reviewed. An initially inclusive approach involving exploration with regression meta-analysis was followed by an analysis of just AQP4 antibody positive cases.
RESULTS
RESULTS
A total of 528 articles were screened to yield 89 articles covering 19,415 individuals from 88 population samples. The female:male sex ratio was significantly influenced by the proportion of AQP4 antibody positive cases in the samples studied (p < 0.001). For AQP4 antibody-positive cases the overall estimate of the sex ratio was 8.89 (95% CI 7.78-10.15). For paediatric populations the estimate was 5.68 (95% CI 4.01-8.03) and for late-onset cases, it was 5.48 (95% CI 4.10-7.33). The mean age of onset was significantly associated with the mean life expectancy of the population sampled (p < 0.001). The mean age of onset for AQP4 antibody-positive cases in long-lived populations was 41.7 years versus 33.3 years in the remainder.
CONCLUSIONS
CONCLUSIONS
The female:male sex ratio and the mean age of onset of AQP4 antibody-associated NMOSD are significantly higher than MS. The sex ratio increases with the proportion of cases that are positive for AQP4 antibodies and the mean age of onset increases with population life expectancy.
Identifiants
pubmed: 38958756
doi: 10.1007/s00415-024-12452-8
pii: 10.1007/s00415-024-12452-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Hesham Abboud
(H)
Orhan Aktas
(O)
Raed Alroughani
(R)
Ayse Altintas
(A)
Metha Apiwattannakul
(M)
Georgina Arrambide
(G)
Jagannadha Avasarala
(J)
Brenda Banwell
(B)
Terrence F Blaschke
(TF)
James Bowen
(J)
Edgar Carnero Contentti
(EC)
Tanuja Chitnis
(T)
Jerome de Seze
(J)
Guillermo Delgado-Garcia
(G)
Irena Dujmovic Basuroski
(I)
Jose Flores
(J)
Kazuo Fujihara
(K)
Lorna Galleguillos
(L)
Benjamin M Greenberg
(BM)
May Han
(M)
Joachim Havla
(J)
Kerstin Hellwig
(K)
Jyh Yung Hor
(JY)
Sven Jarius
(S)
Jorge Andres Jimenez
(JA)
Najib Kissani
(N)
Ingo Kleiter
(I)
Marco Lana-Peixoto
(M)
M Isabel Leite
(MI)
Michael Levy
(M)
Sara Mariotto
(S)
Maureen A Mealy
(MA)
Veronika E Neubrand
(VE)
Celia Oreja-Guevara
(C)
Lekha Pandit
(L)
Sarah M Planchon
(SM)
Anne-Katrin Pröbstel
(AK)
Peiqing Qian
(P)
Chao Quan
(C)
Pavle Repovic
(P)
Claire Riley
(C)
Marius Ringelstein
(M)
Juan I Rojas
(J)
Dalia Rotstein
(D)
Klemens Ruprecht
(K)
Maria José Sá
(MJ)
Albert Saiz
(A)
Sara Salama
(S)
Sasitorn Siritho
(S)
Aksel Siva
(A)
Terry J Smith
(TJ)
Elias S Sotirchos
(ES)
Ibis Soto de Castillo
(IS)
Silvia Tenembaum
(S)
Pablo Villoslada
(P)
Barbara Willekens
(B)
Dean Wingerchuk
(D)
Bassem I Yamout
(BI)
Michael Yeaman
(M)
Informations de copyright
© 2024. Crown.
Références
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189. https://doi.org/10.1212/WNL.0000000000001729
doi: 10.1212/WNL.0000000000001729
pubmed: 26092914
pmcid: 4515040
Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA (2007) Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69(24):2221–2231. https://doi.org/10.1212/01.WNL.0000289761.64862.ce
doi: 10.1212/01.WNL.0000289761.64862.ce
pubmed: 17928579
Santos E, Rocha AL, Oliveira V, Ferro D, Samoes R, Sousa AP, Figueiroa S, Mendonca T, Abreu P, Guimaraes J, Sousa R, Melo C, Correia I, Duraes J, Sousa L, Ferreira J, de Sa J, Sousa F, Sequeira M, Correia AS, Andre AL, Basilio C, Arenga M, Mendes I, Marques IB, Perdigao S, Felgueiras H, Alves I, Correia F, Barroso C, Morganho A, Carmona C, Palavra F, Santos M, Salgado V, Palos A, Nzwalo H, Timoteo A, Guerreiro R, Isidoro L, Boleixa D, Carneiro P, Neves E, Silva AM, Goncalves G, Leite MI, Sa MJ (2021) Neuromyelitis optica spectrum disorders: a nationwide Portuguese clinical epidemiological study. Mult Scler Relat Disord 56:103258. https://doi.org/10.1016/j.msard.2021.103258
doi: 10.1016/j.msard.2021.103258
pubmed: 34583213
Watanabe M, Nakamura Y, Sato S, Niino M, Fukaura H, Tanaka M, Ochi H, Kanda T, Takeshita Y, Yokota T, Nishida Y, Matsui M, Nagayama S, Kusunoki S, Miyamoto K, Mizuno M, Kawachi I, Saji E, Ohashi T, Shimohama S, Hisahara S, Nishiyama K, Iizuka T, Nakatsuji Y, Okuno T, Ochi K, Suzumura A, Yamamoto K, Kawano Y, Tsuji S, Hirata M, Sakate R, Kimura T, Shimizu Y, Nagaishi A, Okada K, Hayashi F, Sakoda A, Masaki K, Shinoda K, Isobe N, Matsushita T, Kira JI (2021) HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data. Sci Rep 11(1):607. https://doi.org/10.1038/s41598-020-79833-7
doi: 10.1038/s41598-020-79833-7
pubmed: 33436735
pmcid: 7804194
Frau J, Coghe G, Lorefice L, Fenu G, Cocco E (2023) The role of microorganisms in the etiopathogenesis of demyelinating diseases. Life (Basel) 13(6):1309. https://doi.org/10.3390/life13061309
doi: 10.3390/life13061309
pubmed: 37374092
Liu S, Tan B, Zhou J, Xiao L, Li M, Yin J (2024) Vitamin D status and the risk of neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. J Clin Neurosci 119:185–192. https://doi.org/10.1016/j.jocn.2023.12.010
doi: 10.1016/j.jocn.2023.12.010
pubmed: 38113581
Davey Smith G (2019) Post-modern epidemiology: when methods meet matter. Am J Epidemiol 188(8):1410–1419. https://doi.org/10.1093/aje/kwz064
doi: 10.1093/aje/kwz064
pubmed: 30877306
pmcid: 6670067
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K (2020) Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11:501. https://doi.org/10.3389/fneur.2020.00501
doi: 10.3389/fneur.2020.00501
pubmed: 32670177
pmcid: 7332882
Wingerchuk DM (2009) Neuromyelitis optica: effect of gender. J Neurol Sci 286(1–2):18–23. https://doi.org/10.1016/j.jns.2009.08.045
doi: 10.1016/j.jns.2009.08.045
pubmed: 19740485
Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, Kleiter I, Chitnis T, Consortium GIC, Biorepository for Neuromyelitis O (2015) Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 21(7):845–853. https://doi.org/10.1177/1352458515572406
Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS, Rodriguez M, Lotze T, Gorman M, Benson L, Belman A, Weinstock-Guttman B, Aaen G, Graves J, Patterson M, Rose JW, Casper TC (2016) Clinical features of neuromyelitis optica in children: US Network of Pediatric MS centers report. Neurology 86(3):245–252. https://doi.org/10.1212/WNL.0000000000002283
doi: 10.1212/WNL.0000000000002283
pubmed: 26683648
pmcid: 4733158
Fragoso YD, Ruocco HH, Dias RM, Cabeca H, Goncalves R, de Carvalho Sousa NA, Spessotto CV, Tauil CB, Alves-Leon SV, Gomes S, Goncalves MVM, Machado SCN, Anacleto A, Correa EC, Pimentel MLV, Santos GAC (2019) Late onset of neuromyelitis optica spectrum disorders. Neurol Ther 8(2):477–482. https://doi.org/10.1007/s40120-019-0143-2
doi: 10.1007/s40120-019-0143-2
pubmed: 31267407
pmcid: 6858916
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114. https://doi.org/10.1212/wnl.53.5.1107
doi: 10.1212/wnl.53.5.1107
pubmed: 10496275
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489. https://doi.org/10.1212/01.wnl.0000216139.44259.74
doi: 10.1212/01.wnl.0000216139.44259.74
pubmed: 16717206
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815. https://doi.org/10.1016/S1474-4422(07)70216-8
doi: 10.1016/S1474-4422(07)70216-8
pubmed: 17706564
Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol 22(3):268–282. https://doi.org/10.1016/S1474-4422(22)00431-8
doi: 10.1016/S1474-4422(22)00431-8
pubmed: 36706773
Boudjani H, Fadda G, Dufort G, Antel J, Giacomini P, Levesque-Roy M, Oskoui M, Duquette P, Prat A, Girard M, Rebillard RM, Meijer I, Pinchefsky E, Nguyen CE, Rossignol E, Rouleau J, Blanchard O, Khairallah N, Beauchemin P, Trudelle AM, Lapointe E, Saveriano A, Larochelle C (2023) Clinical course, imaging, and pathological features of 45 adult and pediatric cases of myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord 76:104787. https://doi.org/10.1016/j.msard.2023.104787
doi: 10.1016/j.msard.2023.104787
pubmed: 37320939
Modig K, Rau R, Ahlbom A (2020) Life expectancy: What does it measure? BMJ Open 10(7):e035932. https://doi.org/10.1136/bmjopen-2019-035932
doi: 10.1136/bmjopen-2019-035932
pubmed: 32699164
pmcid: 7380844
World Health Organization (2020) Life expectancy and health life expectancy data by country. Accessed 24 Oct 2023. World Health Organization, Geneva, Switzerland. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-(years)
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C (2015) Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc 13(3):147–153. https://doi.org/10.1097/XEB.0000000000000054
doi: 10.1097/XEB.0000000000000054
pubmed: 26317388
Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. https://doi.org/10.1186/1471-2288-14-135
doi: 10.1186/1471-2288-14-135
pubmed: 25524443
pmcid: 4383202
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2008) Comprehensive meta-analysis (version 2.2.027). Organ Res Methods 11(1):188–191. https://doi.org/10.1177/1094428106296641
Möller S, Ahrenfeldt LJ (2021) Estimating relative risk when observing zero events-frequentist inference and Bayesian credibility intervals. Int J Env Res Pub Health 18(11):5527. https://doi.org/10.3390/ijerph18115527
doi: 10.3390/ijerph18115527
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 192859
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629
doi: 10.1136/bmj.315.7109.629
pubmed: 9310563
pmcid: 2127453
Naing NN (2000) Easy way to learn standardization: direct and indirect methods. Malays J Med Sci 7(1):10–15
pubmed: 22844209
pmcid: 3406211
United Nations (2022) World population prospects: the 2022 revision. Accessed 24 Oct 2023. United Nations, Department of Economic and Social Affairs, Population Division, New York, NY, USA. https://www.populationpyramid.net/
Aboul-Enein F, Seifert-Held T, Mader S, Kuenz B, Lutterotti A, Rauschka H, Rommer P, Leutmezer F, Vass K, Flamm-Horak A, Stepansky R, Lang W, Fertl E, Schlager T, Heller T, Eggers C, Safoschnik G, Fuchs S, Kraus J, Assar H, Guggenberger S, Reisz M, Schnabl P, Komposch M, Simschitz P, Skrobal A, Moser A, Jeschow M, Stadlbauer D, Freimuller M, Guger M, Schmidegg S, Franta C, Weiser V, Koppi S, Niederkorn-Duft M, Raber B, Schmeissner I, Jecel J, Tinchon A, Storch MK, Reindl M, Berger T, Kristoferitsch W (2013) Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS ONE 8(11):e79649. https://doi.org/10.1371/journal.pone.0079649
Adoni T, Lino AM, da Gama PD, Apostolos-Pereira SL, Marchiori PE, Kok F, Callegaro D (2010) Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Mult Scler 16(1):81–86. https://doi.org/10.1177/1352458509353651
doi: 10.1177/1352458509353651
pubmed: 19995833
Altintas A, Karabudak R, Balci BP, Terzi M, Soysal A, Saip S, Tuncer Kurne A, Uygunoglu U, Nalbantoglu M, Gozubatik Celik G, Isik N, Celik Y, Gokcay F, Duman T, Boz C, Yucesan C, Mangan MS, Celebisoy N, Diker S, Colpak Isikay I, Kansu T, Siva A (2015) Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort: demographic, clinical, and laboratory features. Neurologist 20(4):61–66. https://doi.org/10.1097/NRL.0000000000000057
doi: 10.1097/NRL.0000000000000057
pubmed: 26468870
Alves CS, Santos FBC, Diniz DS (2022) Correlation between Amerindian ancestry and neuromyelitis optica spectrum disorders (NMSOD) among patients in Midwestern Brazil. Arq Neuropsiquiatr 80(5):497–504. https://doi.org/10.1590/0004-282X-ANP-2020-0527
doi: 10.1590/0004-282X-ANP-2020-0527
pubmed: 35766640
pmcid: 9238337
Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO (2011) A population-based study of neuromyelitis optica in Caucasians. Neurology 76(18):1589–1595. https://doi.org/10.1212/WNL.0b013e3182190f74
doi: 10.1212/WNL.0b013e3182190f74
pubmed: 21536639
pmcid: 3269768
Barhate KS, Ganeshan M, Singhal BS (2014) A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol 17(1):77–81. https://doi.org/10.4103/0972-2327.128559
doi: 10.4103/0972-2327.128559
pubmed: 24753665
pmcid: 3992776
Bennis A, El Otmani H, Benkirane N, Harrizi I, El Moutawakil B, Rafai MA, Slassi I (2019) Clinical course of neuromyelitis optica spectrum disorder in a moroccan cohort. Mult Scler Relat Disord 30:141–148. https://doi.org/10.1016/j.msard.2019.02.012
doi: 10.1016/j.msard.2019.02.012
pubmed: 30772672
Bichuetti DB, Oliveira EM, Souza NA, Rivero RL, Gabbai AA (2009) Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler 15(5):613–619. https://doi.org/10.1177/1352458508101935
doi: 10.1177/1352458508101935
pubmed: 19299436
Bizzoco E, Lolli F, Repice AM, Hakiki B, Falcini M, Barilaro A, Taiuti R, Siracusa G, Amato MP, Biagioli T, Lori S, Moretti M, Vinattieri A, Nencini P, Massacesi L, Mata S (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256(11):1891–1898. https://doi.org/10.1007/s00415-009-5171-x
doi: 10.1007/s00415-009-5171-x
pubmed: 19479168
Bukhari W, Prain KM, Waters P, Woodhall M, O’Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA (2017) Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 88(8):632–638. https://doi.org/10.1136/jnnp-2016-314839
doi: 10.1136/jnnp-2016-314839
pubmed: 28550069
Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O, Bellance R, Vernant JC, Smadja D (2001) MS and neuromyelitis optica in Martinique (French West Indies). Neurology 56(4):507–514. https://doi.org/10.1212/wnl.56.4.507
doi: 10.1212/wnl.56.4.507
pubmed: 11222796
Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R (2009) An epidemiological study of neuromyelitis optica in Cuba. J Neurol 256(1):35–44. https://doi.org/10.1007/s00415-009-0009-0
doi: 10.1007/s00415-009-0009-0
pubmed: 19224310
Ceccarelli A, Mifsud VA, Dogar A, Hussain SI (2020) Seropositive neuromyelitis optica spectrum disorder in Emirati patients: a case series. J Clin Neurosci 72:185–190. https://doi.org/10.1016/j.jocn.2019.11.045
doi: 10.1016/j.jocn.2019.11.045
pubmed: 31859181
Chan KH, Lee R, Lee JC, Tse AC, Pang SY, Lau GK, Teo KC, Ho PW (2013) Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. J Neuroimmunol 262(1–2):100–105. https://doi.org/10.1016/j.jneuroim.2013.06.004
doi: 10.1016/j.jneuroim.2013.06.004
pubmed: 23838529
Collongues N, Marignier R, Zephir H, Papeix C, Blanc F, Ritleng C, Tchikviladze M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Creange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, Gout O, Rodriguez D, Wiertlewski S, Laplaud D, Borgel F, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Seze J (2010) Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 74(9):736–742. https://doi.org/10.1212/WNL.0b013e3181d31e35
doi: 10.1212/WNL.0b013e3181d31e35
pubmed: 20194912
Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, Pickersgill T, te Water Naude J, Robertson N (2012) The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 19(4):655–659. https://doi.org/10.1111/j.1468-1331.2011.03529.x
Daoudi S, Bouzar M (2016) Neuromyelitis optica spectrum disorders in Algeria: a preliminary study in the region of Tizi Ouzou. Mult Scler Relat Disord 6:37–40. https://doi.org/10.1016/j.msard.2015.12.005
doi: 10.1016/j.msard.2015.12.005
pubmed: 27063620
Del Negro MC, Marinho PB, Papais-Alvarenga RM (2017) Neuromyelitis optica: phenotypic characteristics in a Brazilian case series. Arq Neuropsiquiatr 75(2):81–86. https://doi.org/10.1590/0004-282X20160193
doi: 10.1590/0004-282X20160193
pubmed: 28226075
Drulovic J, Martinovic V, Basuroski ID, Mesaros S, Mader S, Weinshenker B, Pekmezovic T (2019) Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. Mult Scler Relat Disord 36:101413. https://doi.org/10.1016/j.msard.2019.101413
doi: 10.1016/j.msard.2019.101413
pubmed: 31586803
Eskandarieh S, Nedjat S, Azimi AR, Moghadasi AN, Sahraian MA (2017) Neuromyelitis optica spectrum disorders in Iran. Mult Scler Relat Disord 18:209–212. https://doi.org/10.1016/j.msard.2017.10.007
doi: 10.1016/j.msard.2017.10.007
pubmed: 29141812
Espiritu AI, Mesina BVQ, Puerto AAD, Reyes NGD, Damian LF, Pascual VJ (2019) Neuromyelitis optica spectrum disorder in a tertiary hospital in the Philippines: a case series. Mult Scler Relat Disord 31:124–130. https://doi.org/10.1016/j.msard.2019.04.006
doi: 10.1016/j.msard.2019.04.006
pubmed: 30981191
Etemadifar M, Sabeti F, Ebrahimian S, Momeni F (2020) Dorsal midbrain involvement in MRI as a core clinical manifestation for NMOSD diagnosis. Mult Scler Relat Disord 43:102150. https://doi.org/10.1016/j.msard.2020.102150
doi: 10.1016/j.msard.2020.102150
pubmed: 32416559
Flanagan EP, Cabre P, Weinshenker BG, St Sauver J, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Borders Robinson A, Pittock SJ (2016) Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 79(5):775–783. https://doi.org/10.1002/ana.24617
doi: 10.1002/ana.24617
pubmed: 26891082
pmcid: 4988933
Fukuda TG, Silva ITF, Dos Santos TSS, Filho MBP, de Abreu FF, Oliveira-Filho J (2022) Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurol 22(1):95. https://doi.org/10.1186/s12883-022-02621-5
doi: 10.1186/s12883-022-02621-5
pubmed: 35296261
pmcid: 8925163
Gao M, Yao X, Ding J, Hong R, Wu Y, Huang H, Zhuang L, Li Z, Wang Y, Zhang Y, Guan Y (2019) Low levels of vitamin D and the relationship between vitamin D and Th2 axis-related cytokines in neuromyelitis optica spectrum disorders. J Clin Neurosci 61:22–27. https://doi.org/10.1016/j.jocn.2018.11.024
doi: 10.1016/j.jocn.2018.11.024
pubmed: 30692037
Gracia F, Ramirez D, Parajeles-Vindas A, Diaz A, Diaz de la Fe A, Sanchez NER, Escobar RC, Valle LAG, Weiser R, Santos B, Candelario A, Benzadon A, Araujo P, Valderrama C, Larreategui M, Carrillo G, Gracia K, Vazquez-Cespedes J, Monterrey-Alvarez P, Carazo-Cespedes K, Sanabria-Castro A, Miranda-Loria G, Balmaceda-Meza A, Rivera LIP, Leal IO, Salinas LCR, Thompson A, Torres EL, Pereira DE, Zepeda C, Lopez CA, Valse EAC, Urbina KZC, Urrutia MA, Van Sijtveld I, Armien B, Rivera VM (2022) Neuromyelitis optica spectrum disorder in central America and the caribbean: a multinational clinical characterization study. Neurol Int 14(1):284–293. https://doi.org/10.3390/neurolint14010023
doi: 10.3390/neurolint14010023
pubmed: 35324579
pmcid: 8952282
Holroyd KB, Aziz F, Szolics M, Alsaadi T, Levy M, Schiess N (2018) Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: a multicenter, retrospective study. Clin Exp Neuroimmunol 9(3):155–161. https://doi.org/10.1111/cen3.12458
doi: 10.1111/cen3.12458
pubmed: 30090123
pmcid: 6078000
Hor JY, Lim TT, Chia YK, Ching YM, Cheah CF, Tan K, Chow HB, Arip M, Eow GB, Easaw PES, Leite MI (2018) Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence. Mult Scler Relat Disord 19:20–24. https://doi.org/10.1016/j.msard.2017.10.015
doi: 10.1016/j.msard.2017.10.015
pubmed: 29100047
Ibis SC, Omaira M, Arnoldo S, Elizabeth A, Sandra M, Carlota CM, Elizabeth C, Laura V, Rosalba L, Oscar V, Luisa DM, Nahir A, Hernandez F (2021) Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study. Mult Scler Relat Disord 47:102652. https://doi.org/10.1016/j.msard.2020.102652
doi: 10.1016/j.msard.2020.102652
pubmed: 33279797
Jagtap SA, Mandliya A, Sarada C, Nair MD (2015) Neuromyelitis optica and neuromyelitis optica spectrum disorder: natural history and long-term outcome, an Indian experience. J Neurosci Rural Pract 6(3):331–335. https://doi.org/10.4103/0976-3147.158755
doi: 10.4103/0976-3147.158755
pubmed: 26167014
pmcid: 4481785
Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, McKeon A, Costanzi C, Iorio R, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ (2013) Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81(14):1197–1204. https://doi.org/10.1212/WNL.0b013e3182a6cb5c
doi: 10.1212/WNL.0b013e3182a6cb5c
pubmed: 23997151
pmcid: 3795610
Jonsson DI, Sveinsson O, Hakim R, Brundin L (2019) Epidemiology of NMOSD in Sweden from 1987 to 2013: a nationwide population-based study. Neurology 93(2):e181–e189. https://doi.org/10.1212/WNL.0000000000007746
doi: 10.1212/WNL.0000000000007746
pubmed: 31171648
pmcid: 6656652
Joshi PB, Shah SD, Patel MA, Shah SV, Darji SH, Mirche KC (2022) A study of neuromyelitis optica spectrum disorders (NMOSD): disease pattern based on antibody status. Neurol India 70(3):1131–1136. https://doi.org/10.4103/0028-3886.349679
doi: 10.4103/0028-3886.349679
pubmed: 35864650
Kashipazha D, Mohammadianinejad SE, Majdinasab N, Azizi M, Jafari M (2015) A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iran J Neurol 14(4):204–210
pubmed: 26885339
pmcid: 4754599
Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2012) Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology 78(15):1179–1185. https://doi.org/10.1212/WNL.0b013e31824f8069
doi: 10.1212/WNL.0b013e31824f8069
pubmed: 22459676
Kishk NA, Abdelfattah W, Shalaby NM, Shehata HS, Hassan A, Hegazy MI, Abokrysha NT, Abdellatif D, Shawky SM, Abdo SS, Taha N, Fouad AM, Elmazny A, Ragab AH (2021) The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt. BMC Neurol 21(1):53. https://doi.org/10.1186/s12883-021-02083-1
doi: 10.1186/s12883-021-02083-1
pubmed: 33535985
pmcid: 7860192
Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Kuker W, Chandratre S, Vincent A, Palace J (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276–283. https://doi.org/10.1001/jamaneurol.2013.5857
doi: 10.1001/jamaneurol.2013.5857
pubmed: 24425068
Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kumpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Neuromyelitis Optica Study G (2016) Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol 79(2):206–216. https://doi.org/10.1002/ana.24554
Mealy MA, Kessler RA, Rimler Z, Reid A, Totonis L, Cutter G, Kister I, Levy M (2018) Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm 5(4):e468. https://doi.org/10.1212/NXI.0000000000000468
doi: 10.1212/NXI.0000000000000468
pubmed: 29892608
pmcid: 5994702
Mireles-Ramirez MA, Pacheco-Moises FP, Gonzalez-Usigli HA, Sanchez-Rosales NA, Hernandez-Preciado MR, Delgado-Lara DLC, Hernandez-Cruz JJ, Ortiz GG (2022) Neuromyelitis optica spectrum disorder: pathophysiological approach. Int J Neurosci. https://doi.org/10.1080/00207454.2022.2153046
Mirmosayyeb O, Barzegar M, Afshari-Safavi A, Nehzat N, Heidari A, Emami P, Shaygannejad V (2021) Evaluation of month of birth in neuromyelitis optica spectrum disorders (NMSOD) and multiple sclerosis (MS). Mult Scler Int 2021:8874999. https://doi.org/10.1155/2021/8874999
doi: 10.1155/2021/8874999
pubmed: 34221508
pmcid: 8211531
Miyamoto K, Fujihara K, Kira JI, Kuriyama N, Matsui M, Tamakoshi A, Kusunoki S (2018) Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry 89(6):667–668. https://doi.org/10.1136/jnnp-2017-317321
doi: 10.1136/jnnp-2017-317321
pubmed: 29326292
Netravathi M, Bollampalli HK, Bhat MD, Ganaraja VH, Prasad S, Mahadevan A, Kamble N, Nalini A, Yadav R, Pal PK, Satishchandra P (2019) Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India. Mult Scler Relat Disord 30:85–93. https://doi.org/10.1016/j.msard.2019.01.032
doi: 10.1016/j.msard.2019.01.032
pubmed: 30743086
Pandit L, Kundapur R (2014) Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 20(12):1651–1653. https://doi.org/10.1177/1352458514521503
doi: 10.1177/1352458514521503
pubmed: 24493471
Papais-Alvarenga RM, Vasconcelos CC, Carra A, de Castillo IS, Florentin S, Diaz de Bedoya FH, Mandler R, de Siervi LC, Pimentel ML, Alvarenga MP, Alvarenga MP, Grzesiuk AK, Gama Pereira AB, Gomes Neto AP, Velasquez C, Soublette C, Fleitas CV, Diniz DS, Armas E, Batista E, Hernandez F, Pereira FF, Siqueira HH, Cabeca H, Sanchez J, Brooks JB, Goncalves MV, Barroso MC, Ravelo ME, Castillo MC, Ferreira ML, Rocha MS, Parolin MK, Molina O, Marinho PB, Christo PP, Brant de Souza R, Pessanha Neto S, Camargo SM, Machado SC, Neri VC, Fragoso YD, Alvarenga H, Thuler LC (2015) Central nervous system idiopathic inflammatory demyelinating disorders in south americans: a descriptive, multicenter, cross-sectional study. PLoS ONE 10(7):e0127757. https://doi.org/10.1371/journal.pone.0127757
doi: 10.1371/journal.pone.0127757
pubmed: 26222205
pmcid: 4519274
Papp V, Iljicsov A, Rajda C, Magyari M, Koch-Henriksen N, Petersen T, Jakab G, Deme I, Nagy F, Imre P, Lohner Z, Kovacs K, Birkas AJ, Koves A, Rum G, Nagy Z, Kerenyi L, Vecsei L, Bencsik K, Jobbagy Z, Dioszeghy P, Horvath L, Galantai G, Kasza J, Molnar G, Simo M, Satori M, Rozsa C, Acs P, Berki T, Lovas G, Komoly S, Illes Z (2020) A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. Eur J Neurol 27(2):308–317. https://doi.org/10.1111/ene.14079
doi: 10.1111/ene.14079
pubmed: 31465603
Papp V, Trones KDP, Magyari M, Koch-Henriksen N, Iljicsov A, Rajda C, Nielsen HH, Lovas G, Rozsa C, Kristiansen BH, Stenager E, Frederiksen JL, Komoly S, Sellebjerg F, Petersen T, Illes Z (2021) Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries. Mult Scler Relat Disord 51:102879. https://doi.org/10.1016/j.msard.2021.102879
doi: 10.1016/j.msard.2021.102879
Paz ES, Maciel P, D’Almeida JAC, Silva B, Sampaio HAC, Pinheiro ADV, Carioca AAF, de Melo MLP (2021) Excess weight, central adiposity and pro-inflammatory diet consumption in patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 54:103110. https://doi.org/10.1016/j.msard.2021.103110
doi: 10.1016/j.msard.2021.103110
pubmed: 34214879
Rafiee F, Tarjoman T, Moghadasi AN, Sahraian MA, Azimi A, Rezaeimanesh N, Eskandarieh S (2020) Stressful life events, socioeconomic status, and the risk of neuromyelitis optica spectrum disorder: a population-based case–control study. Mult Scler Relat Disord 46:102544. https://doi.org/10.1016/j.msard.2020.102544
doi: 10.1016/j.msard.2020.102544
pubmed: 33032056
Rivera JF, Kurtzke JF, Booth VJ, Corona VT (2008) Characteristics of Devic’s disease (neuromyelitis optica) in Mexico. J Neurol 255(5):710–715. https://doi.org/10.1007/s00415-008-0781-2
doi: 10.1007/s00415-008-0781-2
pubmed: 18283393
Rojas JI, Alonso Serena M, Garcea O, Patrucco L, Carra A, Correale J, Vrech C, Pappolla A, Miguez J, Doldan ML, Silveira F, Alonso R, Cohen L, Pita C, Silva BA, Fiol M, Gaitan MI, Marrodan M, Negrotto L, Ysrraelit MC, Deri N, Luetic G, Caride A, Carnero Contentti E, Lopez PA, Pettinicchi JP, Curbelo C, Martinez AD, Steinberg JD, Balbuena ME, Tkachuk V, Burgos M, Knorre E, Leguizamon F, Piedrabuena R, Liwacki SDV, Barboza AG, Nofal P, Volman G, Alvez Pinheiro A, Hryb J, Tavolini D, Blaya PA, Silva E, Blanche J, Tizio S, Caceres F, Saladino ML, Zanga G, Fracaro ME, Sgrilli G, Pagani Cassara F, Vazquez G, Sinay V, Menichini ML, Lazaro L, Cabrera LM, Bestoso S, Divi P, Jacobo M, Kohler E, Kohler M, Giunta D, Mainella C, Manzi R, Parada Marcilla M, Viglione JP, Martos I, Reich E, Jose G, Cristiano E, Fernandez Liguori N, on behalf Relevar EMi (2020) Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM). Neurol Sci 41(6):1513–1519. https://doi.org/10.1007/s10072-019-04230-6
doi: 10.1007/s10072-019-04230-6
pubmed: 31960250
Salama S, Marouf H, Ihab Reda M, Mansour AR, ELKholy O, Levy M (2018) Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta. J Neuroimmunol 324:22–25. https://doi.org/10.1016/j.jneuroim.2018.08.014
doi: 10.1016/j.jneuroim.2018.08.014
pubmed: 30199734
pmcid: 6170703
Sepulveda M, Armangue T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jimenez-Huete A, Fernandez-Fournier M, Ramio-Torrenta L, Cobo-Calvo A, Vinals M, de Andres C, Meca-Lallana V, Cervello A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antiguedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A (2016) Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 3(3):e225. https://doi.org/10.1212/NXI.0000000000000225
doi: 10.1212/NXI.0000000000000225
pubmed: 27144216
pmcid: 4841645
Shaygannejad V, Maljaei MB, Bank SS, Mirmosayyeb O, Maracy MR, Askari G (2018) Association between sun exposure, vitamin D intake, serum vitamin D level, and immunoglobulin G level in patients with neuromyelitis optica spectrum disorder. Int J Prev Med 9:68. https://doi.org/10.4103/ijpvm.IJPVM_45_16
doi: 10.4103/ijpvm.IJPVM_45_16
pubmed: 30167098
pmcid: 6106131
Shosha E, Al Asmi A, Nasim E, Inshasi J, Abdulla F, Al Malik Y, Althobaiti A, Alzawahmah M, Alnajashi HA, Binfalah M, AlHarbi A, Thubaiti IA, Ahmed SF, Al-Hashel J, Elyas M, Nandhagopal R, Gujjar A, Harbi TA, Towaijri GA, Alsharooqi IA, AlMaawi A, Al Khathaami AM, Alotaibi N, Nahrir S, Al Rasheed AA, Al Qahtani M, Alawi S, Hundallah K, Jumah M, Alroughani R, with the Guthy-Jackson Charitable Foundation International Clinical C (2020) Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry. Mult Scler Relat Disord 38:101448. https://doi.org/10.1016/j.msard.2019.101448
Singh N, Bhatia R, Bali P, Sreenivas V, Padma MV, Goyal V, Saxena R, Dash D, Garg A, Joseph SL (2021) Clinical features, gender differences, disease course, and outcome in neuromyelitis optica spectrum disorder. Ann Indian Acad Neurol 24(2):186–191. https://doi.org/10.4103/aian.AIAN_334_20
doi: 10.4103/aian.AIAN_334_20
pubmed: 34220061
Stratos K, Lee L, Dai D, Pavenski K, Zuo F, Rotstein D (2020) Evaluation of ethnicity as a predictor of diagnostic phenotype and prognosis in neuromyelitis optica spectrum disorder in Toronto. Canada Mult Scler Relat Disord 40:101950. https://doi.org/10.1016/j.msard.2020.101950
doi: 10.1016/j.msard.2020.101950
pubmed: 31982662
Sun H, Sun X, Li J, Huo Y, Wu L, Huang D, Yu S, Wu W (2017) Gender differences among Chinese patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 17:5–8. https://doi.org/10.1016/j.msard.2017.06.008
doi: 10.1016/j.msard.2017.06.008
pubmed: 29055474
Tarhan B, Rempe T, Rahman S, Rodriguez E, Sladky J, Tuna IS, Rees J (2022) A comparison of pediatric- and adult-onset aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: a review of clinical and radiographic characteristics. J Child Neurol 37(8–9):727–737. https://doi.org/10.1177/08830738221103085
doi: 10.1177/08830738221103085
pubmed: 35673711
Tian DC, Li Z, Yuan M, Zhang C, Gu H, Wang Y, Shi FD (2020) Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study. Lancet Reg Health West Pac 2:100021. https://doi.org/10.1016/j.lanwpc.2020.100021
doi: 10.1016/j.lanwpc.2020.100021
pubmed: 34327375
pmcid: 8315565
van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ (2016) Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol 23(3):580–587. https://doi.org/10.1111/ene.12898
doi: 10.1111/ene.12898
pubmed: 26593750
Wu Y, Yang M, Gao P, Wang Z, Wu J, Wang J, Xu Q, Zhou H, Wu T, Wu W, Wei S, Hu YH (2022) Incidence of neuromyelitis optica spectrum disorders in China: a large cohort study using claim data. BMJ Open 12(1):e048942. https://doi.org/10.1136/bmjopen-2021-048942
doi: 10.1136/bmjopen-2021-048942
pubmed: 35105613
pmcid: 8804634
Yin J, Long Y, Shan F, Fan Y, Wu L, Zhong R, Gao C, Chen X, Gao Q, Yang N (2015) Clinical manifestations of neuromyelitis optica in male and female patients. Neurol Res 37(11):967–973. https://doi.org/10.1179/1743132815Y.0000000081
doi: 10.1179/1743132815Y.0000000081
pubmed: 26213113
Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ (2008) Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 70(5):344–352. https://doi.org/10.1212/01.wnl.0000284600.80782.d5
doi: 10.1212/01.wnl.0000284600.80782.d5
pubmed: 18094334
Camera V, Messina S, Elhadd KT, Sanpera-Iglesias J, Mariano R, Hacohen Y, Dobson R, Meletti S, Wassmer E, Lim MJ, Huda S, Hemingway C, Leite MI, Ramdas S, Palace J (2022) Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 93(1):101–111. https://doi.org/10.1136/jnnp-2021-327206
doi: 10.1136/jnnp-2021-327206
pubmed: 34583946
Collongues N, Marignier R, Zephir H, Papeix C, Fontaine B, Blanc F, Rodriguez D, Fleury M, Vukusic S, Pelletier J, Audoin B, Thouvenot E, Camu W, Barroso B, Ruet A, Brochet B, Vermersch P, Confavreux C, de Seze J (2010) Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 75(12):1084–1088. https://doi.org/10.1212/WNL.0b013e3181f39a66
doi: 10.1212/WNL.0b013e3181f39a66
pubmed: 20855851
Huppke P, Bluthner M, Bauer O, Stark W, Reinhardt K, Huppke B, Gartner J (2010) Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology 75(19):1740–1744. https://doi.org/10.1212/WNL.0b013e3181fc2823
doi: 10.1212/WNL.0b013e3181fc2823
pubmed: 21060098
Lin WS, Wang HP, Chen HM, Lin JW, Lee WT (2020) Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan. J Neurol 267(4):925–932. https://doi.org/10.1007/s00415-019-09647-9
doi: 10.1007/s00415-019-09647-9
pubmed: 31781928
Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV (2008) Spectrum of pediatric neuromyelitis optica. Pediatrics 122(5):e1039–e1047. https://doi.org/10.1542/peds.2007-2758
doi: 10.1542/peds.2007-2758
pubmed: 18838462
Martins C, Moura J, Figueiroa S, Garrido C, Martins J, Samoes R, Guimaraes J, Melo C, Sousa R, Palavra F, Ferreira J, da Silva AM, Sa MJ, Santos E (2022) Pediatric neuromyelitis optica spectrum disorders in Portugal: a multicentre retrospective study. Mult Scler Relat Disord 59:103531. https://doi.org/10.1016/j.msard.2022.103531
doi: 10.1016/j.msard.2022.103531
pubmed: 35078127
McKeon A, Lennon VA, Lotze T, Tenenbaum S, Ness JM, Rensel M, Kuntz NL, Fryer JP, Homburger H, Hunter J, Weinshenker BG, Krecke K, Lucchinetti CF, Pittock SJ (2008) CNS aquaporin-4 autoimmunity in children. Neurology 71(2):93–100. https://doi.org/10.1212/01.wnl.0000314832.24682.c6
doi: 10.1212/01.wnl.0000314832.24682.c6
pubmed: 18509092
Paolilo RB, Hacohen Y, Yazbeck E, Armangue T, Bruijstens A, Lechner C, Apostolos-Pereira SL, Martynenko Y, Breu M, de Medeiros RC, Wassmer E, Baumann M, Papetti L, Capobianco M, Kornek B, Rostasy K, da Paz JA, Ciccarelli O, Lim M, Saiz A, Neuteboom R, Marignier R, Hemingway C, Sato DK, Deiva K (2020) Treatment and outcome of aquaporin-4 antibody-positive NMOSD: a multinational pediatric study. Neurol Neuroimmunol Neuroinflamm 7(5):e837. https://doi.org/10.1212/NXI.0000000000000837
doi: 10.1212/NXI.0000000000000837
pubmed: 32732259
pmcid: 7413715
Yamaguchi Y, Torisu H, Kira R, Ishizaki Y, Sakai Y, Sanefuji M, Ichiyama T, Oka A, Kishi T, Kimura S, Kubota M, Takanashi J, Takahashi Y, Tamai H, Natsume J, Hamano S, Hirabayashi S, Maegaki Y, Mizuguchi M, Minagawa K, Yoshikawa H, Kira J, Kusunoki S, Hara T (2016) A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 87(19):2006–2015. https://doi.org/10.1212/WNL.0000000000003318
doi: 10.1212/WNL.0000000000003318
pubmed: 27742816
pmcid: 5109945
Yoon HH, Park JY, Kim SY, Lee NM, Yi DY, Yun SW, Lim IS, Chae SA (2021) Epidemiology of demyelinating diseases in korean pediatric patients. J Child Neurol 36(2):141–147. https://doi.org/10.1177/0883073820959543
doi: 10.1177/0883073820959543
pubmed: 32988277
Zhou Y, Zhong X, Shu Y, Cui C, Wang J, Wang Y, Li X, Chen Z, Peng L, Kermode A, Qiu W (2019) Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 28:213–220. https://doi.org/10.1016/j.msard.2018.12.038
doi: 10.1016/j.msard.2018.12.038
pubmed: 30623860
Cai LJ, Zhang Q, Zhang Y, Chen HX, Shi ZY, Du Q, Zhou HY (2020) Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 46:102515. https://doi.org/10.1016/j.msard.2020.102515
doi: 10.1016/j.msard.2020.102515
pubmed: 33032051
Carnero Contentti E, Daccach Marques V, Soto de Castillo I, Tkachuk V, Ariel B, Castillo MC, Cristiano E, Diegues Serva GB, Dos Santos AC, Finkelsteyn AM, Lopez PA, Patrucco L, Molina O, Pettinicchi JP, Toneguzzo V, Caride A, Rojas JI (2020) Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort. J Neurol 267(5):1260–1268. https://doi.org/10.1007/s00415-020-09699-2
doi: 10.1007/s00415-020-09699-2
pubmed: 31932911
Collongues N, Marignier R, Jacob A, Leite MI, Siva A, Paul F, Zephir H, Akman-Demir G, Elsone L, Jarius S, Papeix C, Mutch K, Saip S, Wildemann B, Kitley J, Karabudak R, Aktas O, Kuscu D, Altintas A, Palace J, Confavreux C, De Seze J (2014) Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler 20(8):1086–1094. https://doi.org/10.1177/1352458513515085
doi: 10.1177/1352458513515085
pubmed: 24323817
Delgado-Garcia G, Antonio-Luna E, Lopez-Mena D, Rivas-Alonso V, Flores-Rivera J, Corona-Vazquez T (2020) AQP4-IgG-positive neuromyelitis optica spectrum disorder with late onset in Mexico. Mult Scler Relat Disord 43:102221. https://doi.org/10.1016/j.msard.2020.102221
doi: 10.1016/j.msard.2020.102221
pubmed: 32473566
Lavandier N, Bonnan M, Carra-Dalliere C, Charif M, Labauge P, Camdessanche JP, Edan G, Naudin A, Brassat D, Ciron J, Clavelou P, Dulau C, Moroso A, Brochet B, Ouallet JC, on behalf Societe Francophone de la Sclerose en P (2019) First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: a multicentre study. Mult Scler Relat Disord 28:309–312. https://doi.org/10.1016/j.msard.2018.12.016
doi: 10.1016/j.msard.2018.12.016
pubmed: 30665072
Mao Z, Yin J, Zhong X, Zhao Z, Qiu W, Lu Z, Hu X (2015) Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population. BMC Neurol 15:160. https://doi.org/10.1186/s12883-015-0417-y
doi: 10.1186/s12883-015-0417-y
pubmed: 26337073
pmcid: 4558842
Nakahara K, Nakane S, Nagaishi A, Narita T, Matsuo H, Ando Y (2021) Very late onset neuromyelitis optica spectrum disorders. Eur J Neurol 28(8):2574–2581. https://doi.org/10.1111/ene.14901
doi: 10.1111/ene.14901
pubmed: 33960076
Seok JM, Cho HJ, Ahn SW, Cho EB, Park MS, Joo IS, Shin HY, Kim SY, Kim BJ, Kim JK, Cho JY, Huh SY, Kwon O, Lee KH, Kim BJ, Min JH (2017) Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea. Mult Scler 23(13):1748–1756. https://doi.org/10.1177/1352458516685416
doi: 10.1177/1352458516685416
pubmed: 28058965
Sepulveda M, Delgado-Garcia G, Blanco Y, Sola-Valls N, Martinez-Lapiscina EH, Armangue T, Montejo C, Pulido-Valdeolivas I, Martinez-Hernandez E, Arino H, Escudero D, Ruiz-Garcia R, Llufriu S, Dalmau J, Graus F, Saiz A (2019) Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurol Neuroimmunol Neuroinflamm 6(6):e607. https://doi.org/10.1212/NXI.0000000000000607
doi: 10.1212/NXI.0000000000000607
pubmed: 31471461
pmcid: 6745725
Zhang LJ, Yang LN, Li T, Wang J, Qi Y, Zhang DQ, Yang CS, Yang L (2017) Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders. Int J Neurosci 127(4):334–338. https://doi.org/10.1080/00207454.2016.1254630
doi: 10.1080/00207454.2016.1254630
pubmed: 27788616
Bukhari W, Clarke L, O’Gorman C, Khalilidehkordi E, Arnett S, Prain KM, Woodhall M, Silvestrini R, Bundell CS, Ramanathan S, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brownlee W, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Kilpatrick TJ, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonnell RAL, Mason DF, McCombe PA, Pereira J, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt J, Slee M, Taylor BV, Willoughby E, Wilson RJ, Brilot F, Vincent A, Waters P, Broadley SA (2020) The clinical profile of NMOSD in Australia and New Zealand. J Neurol 267(5):1431–1443. https://doi.org/10.1007/s00415-020-09716-4
doi: 10.1007/s00415-020-09716-4
pubmed: 32006158
Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Munch C, Winkelmann A, Zettl UU, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. https://doi.org/10.1186/1742-2094-9-14
doi: 10.1186/1742-2094-9-14
pubmed: 22260418
pmcid: 3283476
Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, Nishizawa M, Sakimura K, Tanaka K (2011) Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 82(12):1360–1364. https://doi.org/10.1136/jnnp-2011-300403
doi: 10.1136/jnnp-2011-300403
pubmed: 21665917
Alvarenga MP, Schimidt S, Alvarenga RP (2017) Epidemiology of neuromyelitis optica in Latin America. Mult Scler J Exp Transl Clin 3(3):2055217317730098. https://doi.org/10.1177/2055217317730098
doi: 10.1177/2055217317730098
pubmed: 28979797
pmcid: 5617096
Asgari N, Lillevang ST, Skejoe HPB, Kyvik KO (2019) Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998–2008, 2007–2014). Brain Behav 9(7):e01338. https://doi.org/10.1002/brb3.1338
doi: 10.1002/brb3.1338
pubmed: 31187587
pmcid: 6625475
Ashtari F, Safaei A, Shaygannejad V, Najafi MA, Vesal S (2017) Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: a cross-sectional study. J Res Med Sci 22:41. https://doi.org/10.4103/1735-1995.202142
doi: 10.4103/1735-1995.202142
pubmed: 28465700
pmcid: 5393101
Badihian S, Manouchehri N, Mirmosayyeb O, Ashtari F, Shaygannejad V (2018) Neuromyelitis optica spectrum disorder and menstruation. Rev Neurol (Paris) 174(10):716–721. https://doi.org/10.1016/j.neurol.2018.01.373
doi: 10.1016/j.neurol.2018.01.373
pubmed: 30049560
Bergamaschi R, Ghezzi A (2004) Devic’s neuromyelitis optica: clinical features and prognostic factors. Neurol Sci 25(Suppl 4):S364–S367. https://doi.org/10.1007/s10072-004-0342-0
doi: 10.1007/s10072-004-0342-0
pubmed: 15727235
Bukhari W, Khalilidehkordi E, Mason DF, Barnett MH, Taylor BV, Fabis-Pedrini M, Kermode AG, Subramanian S, Waters P, Broadley SA, New Zealand NMOC (2022) NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. J Neurol 269(2):836–845. https://doi.org/10.1007/s00415-021-10665-9
doi: 10.1007/s00415-021-10665-9
pubmed: 34213614
Cabre P, Gonzalez-Quevedo A, Lannuzel A, Bonnan M, Merle H, Olindo S, Chausson N, Lara-Rodriguez R, Smadja D, Cabrera-Gomez J (2009) Descriptive epidemiology of neuromyelitis optica in the Caribbean basin. Rev Neurol (Paris) 165(8–9):676–683. https://doi.org/10.1016/j.neurol.2009.02.012
doi: 10.1016/j.neurol.2009.02.012
pubmed: 19406445
Carnero Contentti E, Daccach Marques V, Soto de Castillo I, Tkachuk V, Lopez PA, Rojas JI (2020) Age at onset correlate with disability in Latin American aquaporin-4-IgG-positive NMOSD patients. Mult Scler Relat Disord 44:102258. https://doi.org/10.1016/j.msard.2020.102258
doi: 10.1016/j.msard.2020.102258
pubmed: 32521482
Cheng Q, Miao L, Zhang J, Guan YT, Liu ZG, Wang X, Sun XJ, Zhao ZX, Song YJ, Ding XY, Guo ZI, Cheng XJ, Chen SD, Jiang GX, Fredrikson S (2008) Clinical features of patients with multiple sclerosis from a survey in Shanghai. China Mult Scler 14(5):671–678. https://doi.org/10.1177/1352458507087844
doi: 10.1177/1352458507087844
pubmed: 18424476
Choy BNK, Ng ALK, Lai JSM (2018) Clinical characteristics of optic neuritis in Hong Kong population: 10-year review. Int Ophthalmol 38(2):557–564. https://doi.org/10.1007/s10792-017-0491-9
doi: 10.1007/s10792-017-0491-9
pubmed: 28289949
Collongues N, Marignier R, Zephir H, Blanc F, Vukusic S, Outteryck O, Fleury M, Ruet A, Borgel F, Thouvenot E, Moreau T, Defer G, Derache N, Pelletier J, Audoin B, Debouverie M, Labauge P, Gout O, Camu W, Brassat D, Brochet B, Vermersch P, Confavreux C, de Seze J (2011) High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Mult Scler 17(6):720–724. https://doi.org/10.1177/1352458510396923
doi: 10.1177/1352458510396923
pubmed: 21239412
Cristiano E, Patrucco L, Miguez J, Giunta D, Peroni J, Rojas JI (2016) Increasing incidence of multiple sclerosis among women in Buenos Aires: a 22 year health maintenance organization based study. Neurol Sci 37(10):1621–1626. https://doi.org/10.1007/s10072-016-2637-3
doi: 10.1007/s10072-016-2637-3
pubmed: 27338941
Dale GH, Svendsen KB, Gjelstrup MC, Christensen T, Houen G, Nielsen E, Bek T, Petersen T (2018) Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. Acta Neurol Scand 137(6):582–588. https://doi.org/10.1111/ane.12903
doi: 10.1111/ane.12903
pubmed: 29359475
Domingos J, Isidoro L, Figueiredo R, Brum M, Capela C, Barros P, Santos E, Macario Mdo C, Pinto Marques J, Pedrosa R, Vale J, Sa MJ (2015) Neuromyelitis optica in Portugal (NEMIPORT)—a multicentre study. Clin Neurol Neurosurg 134:79–84. https://doi.org/10.1016/j.clineuro.2015.04.001
doi: 10.1016/j.clineuro.2015.04.001
pubmed: 25965287
Eskandarieh S, Nedjat S, Abdollahpour I, Moghadasi AN, Azimi AR, Sahraian MA (2017) Comparing epidemiology and baseline characteristic of multiple sclerosis and neuromyelitis optica: a case–control study. Mult Scler Relat Disord 12:39–43. https://doi.org/10.1016/j.msard.2017.01.004
doi: 10.1016/j.msard.2017.01.004
pubmed: 28283104
Eskandarieh S, Nedjat S, Abdollahpour I, Azimi AR, Moghadasi AN, Asgari N, Sahraian MA (2018) Environmental risk factors in neuromyelitis optica spectrum disorder: a case–control study. Acta Neurol Belg 118(2):277–287. https://doi.org/10.1007/s13760-018-0900-5
doi: 10.1007/s13760-018-0900-5
pubmed: 29500680
Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z (2014) An epidemiological study of neuromyelitis optica in Isfahan. Mult Scler 20(14):1920–1922. https://doi.org/10.1177/1352458514537699
doi: 10.1177/1352458514537699
pubmed: 24948686
Etemadifar M, Mehrbod N, Dehghani L, Golabbakhsh A, Fereidan-Esfahani M, Akbari M, Nasr Z (2014) Prevalence of Lhermitte’s sign in multiple sclerosis versus neuromyelitis optica. Iran J Neurol 13(1):50–51
pubmed: 24800049
pmcid: 3968359
Fragoso YD, Sousa NAC, Saad T, Alves-Leon SV, Pimentel MLV, Goncalves MVM, Stella CV, Diniz DS, Santos GC, Gomes S, Adoni T, Anacleto A, Claudino R, Malfetano FR, Winckler TCD, Damasceno A, Eboni ACB, Farinhas JGD, Mota RSS (2019) Clinical characteristics of patients with neuromyelitis optica spectrum disorders with early onset. J Child Neurol 34(9):487–490. https://doi.org/10.1177/0883073819842421
doi: 10.1177/0883073819842421
pubmed: 31012355
Gold SM, Willing A, Leypoldt F, Paul F, Friese MA (2019) Sex differences in autoimmune disorders of the central nervous system. Semin Immunopathol 41(2):177–188. https://doi.org/10.1007/s00281-018-0723-8
doi: 10.1007/s00281-018-0723-8
pubmed: 30361800
Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Calvo AC, Olascoaga J, Ramio-Torrenta L, Reindl M, Benito-Leon J, Casanova B, Arrambide G, Sabater L, Graus F, Dalmau J, Saiz A (2015) Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21(7):866–874. https://doi.org/10.1177/1352458514555785
doi: 10.1177/1352458514555785
pubmed: 25344373
Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, Sasaki H (2012) Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 323(1–2):117–122. https://doi.org/10.1016/j.jns.2012.08.032
doi: 10.1016/j.jns.2012.08.032
pubmed: 22995683
Houzen H, Kondo K, Horiuchi K, Niino M (2018) Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. Eur J Neurol 25(2):334–339. https://doi.org/10.1111/ene.13506
doi: 10.1111/ene.13506
pubmed: 29105222
Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M (2013) The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 260(8):2134–2137. https://doi.org/10.1007/s00415-013-6926-y
doi: 10.1007/s00415-013-6926-y
pubmed: 23689970
Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, Franciotta D, Ruprecht K, Kuenz B, Rommer P, Kristoferitsch W, Wildemann B, Vincent A (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1–2):158–162. https://doi.org/10.1016/j.jns.2010.07.011
doi: 10.1016/j.jns.2010.07.011
pubmed: 20850793
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M, in cooperation with the Neuromyelitis Optica Study G (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13(1):279. https://doi.org/10.1186/s12974-016-0717-1
Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ (2018) Racial differences in neuromyelitis optica spectrum disorder. Neurology 91(22):e2089–e2099. https://doi.org/10.1212/WNL.0000000000006574
doi: 10.1212/WNL.0000000000006574
pubmed: 30366977
pmcid: 6282238
Kim JE, Park SH, Han K, Kim HJ, Shin DW, Kim SM (2020) Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea. Mult Scler 26(14):1837–1844. https://doi.org/10.1177/1352458519888609
doi: 10.1177/1352458519888609
pubmed: 31749401
Krumbholz M, Hofstadt-van Oy U, Angstwurm K, Kleiter I, Jarius S, Paul F, Aktas O, Buchholz G, Kern P, Straube A, Kumpfel T (2015) Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol 262(5):1379–1384. https://doi.org/10.1007/s00415-015-7766-8
doi: 10.1007/s00415-015-7766-8
pubmed: 25957640
pmcid: 4441737
Lee JD, Guimond C, Yee IM, Vilarino-Guell C, Wu ZY, Traboulsee AL, Sadovnick AD (2015) Incidence of multiple sclerosis and related disorders in Asian Populations of British Columbia. Can J Neurol Sci 42(4):235–241. https://doi.org/10.1017/cjn.2015.36
doi: 10.1017/cjn.2015.36
pubmed: 26074012
Lee HL, Kim JY, Seok JM, Hong YH, Lim NG, Shin HY, Kim BJ, Hwang SY, Min JH, Kim BJ (2020) Prevalence and incidence of neuromyelitis optica spectrum disorder in Korea: population based study. J Korean Med Sci 35(17):e115. https://doi.org/10.3346/jkms.2020.35.e115
doi: 10.3346/jkms.2020.35.e115
pubmed: 32356417
pmcid: 7200182
Li Y, Zhang J, Zhou Y, Xie H, Duan R, Jing L, Yao Y, Teng J, Jia Y (2021) Analysis of predictive risk factors in aquaporin-4-IgG positive highly active neuromyelitis optica spectrum disorders. Front Neurol 12:731835. https://doi.org/10.3389/fneur.2021.731835
doi: 10.3389/fneur.2021.731835
pubmed: 34512539
pmcid: 8427300
Marignier R, Cobo Calvo A, Vukusic S (2017) Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol 30(3):208–215. https://doi.org/10.1097/WCO.0000000000000455
doi: 10.1097/WCO.0000000000000455
pubmed: 28306572
Mealy MA, Wingerchuk DM, Greenberg BM, Levy M (2012) Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 69(9):1176–1180. https://doi.org/10.1001/archneurol.2012.314
doi: 10.1001/archneurol.2012.314
pubmed: 22733096
O’Connell K, Hamilton-Shield A, Woodhall M, Messina S, Mariano R, Waters P, Ramdas S, Leite MI, Palace J (2020) Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire. UK J Neurol Neurosurg Psychiatry 91(10):1126–1128. https://doi.org/10.1136/jnnp-2020-323158
doi: 10.1136/jnnp-2020-323158
pubmed: 32576617
Ortiz Salas PA, Gaviria Carrillo M, Cortes Bernal GA, Moreno Medina K, Roa LF, Rodriguez Quintana JH (2022) Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective. Neurologia (Engl Ed) 38(7):504–510. https://doi.org/10.1016/j.nrleng.2020.08.022
doi: 10.1016/j.nrleng.2020.08.022
pubmed: 35637138
Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger CC, Roemer SF, Jensen MB, Petersen AE, Nielsen HH, Rosendahl L, Mezei Z, Christensen T, Svendsen K, Hyldgaard Jensen PE, Lydolph MC, Heegaard N, Frederiksen JL, Sellebjerg F, Stenager E, Petersen T (2018) Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 91(24):e2265–e2275. https://doi.org/10.1212/WNL.0000000000006645
doi: 10.1212/WNL.0000000000006645
pubmed: 30413632
pmcid: 6329324
Park TJ, Kim JH, Kim HJ, Bae JS, Cheong HS, Park BL, Shin HD (2014) Lack of association between AQP4 polymorphisms and risk of inflammatory demyelinating disease in a Korean population. Gene 536(2):302–307. https://doi.org/10.1016/j.gene.2013.12.007
doi: 10.1016/j.gene.2013.12.007
pubmed: 24361961
Pittock SJ, Lennon VA, Bakshi N, Shen L, McKeon A, Quach H, Briggs FB, Bernstein AL, Schaefer CA, Barcellos LF (2014) Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis. JAMA Neurol 71(11):1433–1436. https://doi.org/10.1001/jamaneurol.2014.1581
doi: 10.1001/jamaneurol.2014.1581
pubmed: 25178362
Rezaeimanesh N, Sahraian MA, Moghadasi AN, Eskandarieh S (2020) Epidemiology of neuromyelitis optica spectrum disorder in Tehran, Iran: the prevalence, baseline characteristics, and clinical aspects. Neurol Sci 41(9):2647–2648. https://doi.org/10.1007/s10072-020-04393-7
doi: 10.1007/s10072-020-04393-7
pubmed: 32306139
Sahraian MA, Moinfar Z, Khorramnia S, Ebrahim MM (2010) Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 17(6):794–799. https://doi.org/10.1111/j.1468-1331.2009.02928.x
doi: 10.1111/j.1468-1331.2009.02928.x
pubmed: 20100229
Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F, Spanish-Italian NMOSG (2007) Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 254(9):1233–1237. https://doi.org/10.1007/s00415-007-0509-8
Sepulveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martinez-Yelamos S, Sola-Valls N, Armangue T, Sotoca J, Escartin A, Robles-Cedeno R, Ramio-Torrenta L, Presas-Rodriguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervas M, Mane-Martinez MA, Cano A, Vela E, Tintore M, Blanco Y, Montalban X, Graus F, Saiz A (2018) Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler 24(14):1843–1851. https://doi.org/10.1177/1352458517735191
doi: 10.1177/1352458517735191
pubmed: 28984163
Simaniv TO, Kochergin IA, Zakharova MN, Korobko DS, Zaslavskii LG, Zelenova OV, Abramov SI (2021) [Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population]. Zh Nevrol Psikhiatr Im S S Korsakova 121(7):96–103. https://doi.org/10.17116/jnevro202112107196
Vanikieti K, Poonyathalang A, Jindahra P, Bouzika P, Rizzo JF 3rd, Cestari DM (2017) Clinical characteristics and long-term visual outcome of optic neuritis in neuromyelitis optica spectrum disorder: a comparison between Thai and American-Caucasian cohorts. Mult Scler Relat Disord 17:87–91. https://doi.org/10.1016/j.msard.2017.07.013
doi: 10.1016/j.msard.2017.07.013
pubmed: 29055481
Wang H, Dai Y, Qiu W, Zhong X, Wu A, Wang Y, Lu Z, Bao J, Hu X (2011) HLA-DPB1 0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in southern Han Chinese. J Neuroimmunol 233(1–2):181–184. https://doi.org/10.1016/j.jneuroim.2010.11.004
doi: 10.1016/j.jneuroim.2010.11.004
pubmed: 21130504
Mumford CJ, Fraser MB, Wood NW, Compston DA (1992) Multiple sclerosis in the Cambridge health district of east Anglia. J Neurol Neurosurg Psychiatry 55(10):877–82. 1015180
Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, Kuriyama N, Kuwabara S, Nakashima I (2023) Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler 29(4–5):530–539. https://doi.org/10.1177/13524585231156736
doi: 10.1177/13524585231156736
pubmed: 36905136
Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S, Jr., Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H, Group MSS, the New Zealand MSPSG (2012) Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS ONE 7(10):e48078. https://doi.org/10.1371/journal.pone.0048078
Silcocks PB, Jenner DA, Reza R (2001) Life expectancy as a summary of mortality in a population: statistical considerations and suitability for use by health authorities. J Epidemiol Community Health 55(1):38–43. https://doi.org/10.1136/jech.55.1.38
doi: 10.1136/jech.55.1.38
pubmed: 11112949
pmcid: 1731769
Rider V, Abdou NI, Kimler BF, Lu N, Brown S, Fridley BL (2018) Gender bias in human systemic lupus erythematosus: A problem of steroid receptor action? Front Immunol 9:611. https://doi.org/10.3389/fimmu.2018.00611
doi: 10.3389/fimmu.2018.00611
pubmed: 29643853
pmcid: 5882779
Kvarnstrom M, Ottosson V, Nordmark B, Wahren-Herlenius M (2015) Incident cases of primary Sjogren’s syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol 44(2):135–142. https://doi.org/10.3109/03009742.2014.931457
doi: 10.3109/03009742.2014.931457
pubmed: 25222653
Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zephir H, Moder K, Weinshenker BG (2008) Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol 65(1):78–83. https://doi.org/10.1001/archneurol.2007.17
doi: 10.1001/archneurol.2007.17
pubmed: 18195142
Desai MK, Brinton RD (2019) Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. Front Endocrinol (Lausanne) 10:265. https://doi.org/10.3389/fendo.2019.00265
doi: 10.3389/fendo.2019.00265
pubmed: 31110493
Romero-Pinel L, Bau L, Matas E, Leon I, Munoz-Vendrell A, Arroyo P, Masuet-Aumatell C, Martinez-Yelamos A, Martinez-Yelamos S (2022) The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades. Mult Scler Relat Disord 68:104103. https://doi.org/10.1016/j.msard.2022.104103
doi: 10.1016/j.msard.2022.104103
pubmed: 36029708
Hooge JP, Redekop WK (1992) Multiple sclerosis with very late onset. Neurology 42(10):1907–1910. https://doi.org/10.1212/wnl.42.10.1907
doi: 10.1212/wnl.42.10.1907
pubmed: 1407571
Bermel RA, Rae-Grant AD, Fox RJ (2010) Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy. Mult Scler 16(11):1335–1340. https://doi.org/10.1177/1352458510377334
doi: 10.1177/1352458510377334
pubmed: 20670982
McGrogan A, Madle GC, Seaman HE, de Vries CS (2009) The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 32(2):150–163. https://doi.org/10.1159/000184748
doi: 10.1159/000184748
pubmed: 19088488
Childs B, Scriver CR (1986) Age at onset and causes of disease. Perspect Biol Med 29(3):437–460. https://doi.org/10.1353/pbm.1986.0056
doi: 10.1353/pbm.1986.0056
pubmed: 3714435
Lee JY, Chitnis T (2016) Pediatric multiple sclerosis. Semin Neurol 36(2):148–153. https://doi.org/10.1055/s-0036-1579738
doi: 10.1055/s-0036-1579738
pubmed: 27116721
Li Y, Xie H, Zhang J, Zhou Y, Jing L, Yao Y, Duan R, Jia Y (2021) Clinical and radiological characteristics of children and adults with first-attack myelin oligodendrocyte glycoprotein antibody disease and analysis of risk factors for predicting the severity at disease onset in central China. Front Immunol 12:752557. https://doi.org/10.3389/fimmu.2021.752557
doi: 10.3389/fimmu.2021.752557
pubmed: 34975841
pmcid: 8714638